Francois Brisebois
Stock Analyst at Oppenheimer
(2.18)
# 2,889
Out of 5,049 analysts
88
Total ratings
39.77%
Success rate
-2.17%
Average return
Main Sectors:
Stocks Rated by Francois Brisebois
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AQST Aquestive Therapeutics | Maintains: Outperform | $7 → $8 | $6.08 | +31.58% | 3 | Sep 8, 2025 | |
| SVRA Savara | Maintains: Outperform | $5 → $6 | $4.13 | +45.28% | 6 | Aug 15, 2025 | |
| SNSE Sensei Biotherapeutics | Maintains: Outperform | $70 → $80 | $8.68 | +821.66% | 2 | Mar 28, 2025 | |
| ABEO Abeona Therapeutics | Initiates: Outperform | $16 | $4.56 | +250.88% | 1 | Mar 5, 2025 | |
| OVID Ovid Therapeutics | Upgrades: Outperform | $4 | $1.33 | +200.75% | 1 | Jan 29, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Outperform | $65 → $72 | $71.50 | +0.70% | 7 | Jan 22, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $59 → $61 | $30.72 | +98.57% | 6 | Jan 13, 2025 | |
| MNMD Mind Medicine (MindMed) | Reiterates: Outperform | $20 | $12.00 | +66.67% | 4 | Dec 17, 2024 | |
| TRDA Entrada Therapeutics | Maintains: Outperform | $25 → $28 | $6.62 | +322.96% | 2 | Nov 6, 2024 | |
| AVDL Avadel Pharmaceuticals | Maintains: Outperform | $29 → $30 | $18.90 | +58.73% | 8 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $143 → $163 | $171.75 | -5.09% | 4 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $55 | $21.52 | +155.58% | 5 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $0.75 | +1,896.01% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 | $6.71 | -10.58% | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $4.81 | +128.69% | 6 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $23.74 | -41.03% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $4.32 | +478.70% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $65 | $17.00 | +282.35% | 5 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $4.92 | +103.25% | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $152 | $6.17 | +2,363.53% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $36 | $17.78 | +102.47% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $60 | $0.35 | +17,241.04% | 3 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7,200 → $5,400 | $1.70 | +317,547.06% | 2 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $11 | $3.11 | +254.27% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $18 | $4.76 | +278.15% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $6.63 | +654.15% | 1 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,240 | $1.19 | +272,123.16% | 1 | Feb 4, 2020 |
Aquestive Therapeutics
Sep 8, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $6.08
Upside: +31.58%
Savara
Aug 15, 2025
Maintains: Outperform
Price Target: $5 → $6
Current: $4.13
Upside: +45.28%
Sensei Biotherapeutics
Mar 28, 2025
Maintains: Outperform
Price Target: $70 → $80
Current: $8.68
Upside: +821.66%
Abeona Therapeutics
Mar 5, 2025
Initiates: Outperform
Price Target: $16
Current: $4.56
Upside: +250.88%
Ovid Therapeutics
Jan 29, 2025
Upgrades: Outperform
Price Target: $4
Current: $1.33
Upside: +200.75%
Tarsus Pharmaceuticals
Jan 22, 2025
Maintains: Outperform
Price Target: $65 → $72
Current: $71.50
Upside: +0.70%
Harmony Biosciences Holdings
Jan 13, 2025
Maintains: Outperform
Price Target: $59 → $61
Current: $30.72
Upside: +98.57%
Mind Medicine (MindMed)
Dec 17, 2024
Reiterates: Outperform
Price Target: $20
Current: $12.00
Upside: +66.67%
Entrada Therapeutics
Nov 6, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $6.62
Upside: +322.96%
Avadel Pharmaceuticals
Oct 31, 2024
Maintains: Outperform
Price Target: $29 → $30
Current: $18.90
Upside: +58.73%
Oct 31, 2024
Maintains: Outperform
Price Target: $143 → $163
Current: $171.75
Upside: -5.09%
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $21.52
Upside: +155.58%
Aug 19, 2024
Reiterates: Outperform
Price Target: $15
Current: $0.75
Upside: +1,896.01%
Aug 16, 2024
Reiterates: Outperform
Price Target: $6
Current: $6.71
Upside: -10.58%
Aug 15, 2024
Reiterates: Outperform
Price Target: $11
Current: $4.81
Upside: +128.69%
Aug 14, 2024
Reiterates: Outperform
Price Target: $14
Current: $23.74
Upside: -41.03%
Jun 25, 2024
Initiates: Outperform
Price Target: $25
Current: $4.32
Upside: +478.70%
Jun 13, 2024
Maintains: Outperform
Price Target: $55 → $65
Current: $17.00
Upside: +282.35%
May 6, 2024
Reiterates: Outperform
Price Target: $10
Current: $4.92
Upside: +103.25%
Aug 30, 2023
Reiterates: Outperform
Price Target: $152
Current: $6.17
Upside: +2,363.53%
Aug 17, 2023
Maintains: Outperform
Price Target: $63 → $36
Current: $17.78
Upside: +102.47%
Apr 3, 2023
Maintains: Outperform
Price Target: $100 → $60
Current: $0.35
Upside: +17,241.04%
Feb 6, 2023
Maintains: Outperform
Price Target: $7,200 → $5,400
Current: $1.70
Upside: +317,547.06%
Aug 29, 2022
Maintains: Outperform
Price Target: $17 → $11
Current: $3.11
Upside: +254.27%
Jul 18, 2022
Assumes: Outperform
Price Target: $18
Current: $4.76
Upside: +278.15%
Oct 29, 2021
Initiates: Outperform
Price Target: $50
Current: $6.63
Upside: +654.15%
Feb 4, 2020
Initiates: Buy
Price Target: $3,240
Current: $1.19
Upside: +272,123.16%